CORALVILLE, Iowa, Oct. 15, 2018 /PRNewswire/ -- CIVCO Radiotherapy, the leading global provider of high quality, innovative, patient-centric radiotherapy solutions, is delighted to announce FDA 510k clearance and EU CE mark for their Solstice™ SRS Immobilization System. The product will be available for shipment following its display at the American Society for Radiation Oncology (ASTRO) Meeting taking place October 21-24, 2018 in San Antonio, Texas.
The Solstice SRS Immobilization System offers unique corrective pitch capability and positioning flexibility. It features customizable components that create a comfortable head and neck immobilization system for precise radiotherapy treatments to improve patient outcomes. The system is comprised of a carbon fiber head support, customizable cushion and dedicated thermoplastic mask designed for secure and simple attachment.
"The Solstice SRS Immobilization System is the only midline thermoplastic mask system on the market with variable pitch capability, increasing setup options in CT simulation and allowing positioning flexibility during treatment," commented John Steffen, Director of Product Management at CIVCO. "We are excited that clearance in the U.S. and EU CE marking opens opportunities for us to provide this unique solution to radiotherapy clinics to help improve patient outcomes."
About CIVCO Radiotherapy
CIVCO Radiotherapy has over 35 years' experience developing, manufacturing and providing high-quality, innovative, patient-centric solutions in radiotherapy. These solutions include: advanced patient immobilization and positioning hardware and consumables, fiducial markers, couchtops and overlays, software, patient care products and advanced 6DOF robotic patient positioning.
